A Safety and Pharmacokinetics Study of TL-003 in Healthy Adults and Open-label Assessments in Participants With Ulcerative Colitis

A Phase 1 Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of TL-003 in Healthy Adult Participants and Open-label Assessments in Participants With Ulcerative Colitis

The goal of this study is to evaluate safety, tolerability, pharmacokinetics (PK)), pharmacodynamics (PD) and immunogenicity of single and multiple ascending dose of TL-003 in healthy adult participants.

Study Overview

• Status: Recruiting
• Conditions: Healthy Volunteer
• Intervention / Treatment: Drug: Placebo; Drug: TL-003

• Study Type: Interventional
• Enrollment (Estimated): 48
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Peter Schrader, Doctor of Medicine; Phone Number: 61 08 63825100; Email: pschrader@linear.org.au

Study Locations

• Australia
  • Western Australia
    • Perth, Western Australia, Australia, 6009
      • Recruiting
      • Linear Early Phase Ltd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male or female between 18 and 55 years of age.
• Body mass index (BMI) between 18.0 to 32.0 kg/m2 (inclusive), Body weight ≥ 50 kg for males and ≥ 45 kg for females.
• Able to participate and comply with all study procedures and restrictions, and willing to provide written informed consent to participate in the study.

• Female participants who are not pregnant or breastfeeding and meet at least one of the following conditions:

  1. Not of childbearing potential
  2. Of childbearing potential and agrees to use a highly effective method of contraception plus condom use consistently from 30 days prior to Day 1 until the EOS visit.
  3. Should not donate ova from Day 1 until the EOS Visit.
• Male participants must use condom if sexually active with females of childbearing potential from Day 1 until the EOS visit. The female partner of a male participant who does not meet the definition of postmenopausal or permanently surgically sterile is considered of childbearing potential and is required to use a highly effective method of contraception consistently from 30 days prior to Day 1 until the EOS visit of the male participant. Male participants who are surgically sterilized, performed at least 6 months prior to screening, may be enrolled. Male participants must also agree not to donate sperm from Day 1 until the EOS visit.
• No clinically significant findings as determined by medical history, and by results of physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests obtained within 28 days prior to study treatment administration.

Exclusion Criteria:

• History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the participants.
• History of immunological abnormality (i.e., primary or secondary immune suppression) that could interfere with the objectives of the study or the safety of the participants.
• Presence or history of any abnormality or illness, which in the opinion of the Investigator (or designee) may affect absorption, distribution, metabolism or elimination of the study treatment.

• Any screening laboratory evaluation outside the laboratory reference range that is judged by the Investigator (or designee) to be clinically significant, including but not limited to:

  1. Participants with estimated glomerular filtration rate (eGFR) < 80 mL/min/1.73m2 as determined by the CKD-EPI 2021 formula, at the Screening or Baseline visits.
  2. Alanine amino transferase (ALT) or aspartate amino transferase (AST) >1.5 times upper limit of normal (ULN), which remains similar upon repeat, at the Screening or Baseline visits.
  3. Total bilirubin > 1.5 × ULN at the Screening or Baseline visits. Total bilirubin > 1.5 × ULN is acceptable if, direct bilirubin < 40%, normal AST/ALT/ alkaline phosphatase (ALP), and no evidence of hemolysis, according to Investigator (or designee) discretion.
  4. White blood cell count < 3,000 cells/mm3 (< 3.0×10 9/L) or any abnormal evaluations judged clinically significant by the Investigator (or designee) at the Screening or Baseline visits. Note: If the test results meet the above criteria, a repeat test may be performed to determine eligibility.
• Blood pressure and heart rate are outside the ranges 90-140 mmHg systolic, 50-90 mmHg diastolic, heart rate 40-100 beats/min.
• 12-lead ECG with any abnormality judged by the Investigator (or designee) to be clinically significant, or QTcF interval of > 450 msec for men or > 470 msec for women.
• Major surgery or major traumatic injury within 3 months of Day 1. Participants must have also fully recovered from any surgery and/or its complications before initiating the study treatment.
• Malignancy or a history of malignancy prior to the Screening Visit (except for nonmelanoma cutaneous malignancies which have been fully treated and completed posttreatment follow-up).
• History of or current active tuberculosis (TB) infection; history of latent TB or current latent TB infection as indicated by a positive QuantiFERON-TB test (or equivalent).

• Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV) antibodies at Screening visit as defined below:

  1. Hepatitis B virus (HBV): Positive test for HBsAg.
  2. HCV: Positive test for hepatitis C antibody and a positive test for HCV RNA.
  3. HIV: Positive test for HIV antibody.

• Other active infections or history of infections as follows:

  1. Infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 14 days before the Baseline (Day 1) Visit.
  2. A serious infection, defined as requiring hospitalization or IV anti-microbial therapy within 2 months prior to the Baseline (Day 1) Visit.
  3. A history of opportunistic, recurrent, or chronic infections at Investigator's (or designee's) discretion.
• History of significant allergy to any medication as judged by the Investigator (or designee).
• Use of any prescription medication within 14 days prior to D1 or 5 half-lives, whichever is longer; or use of over-the-counter medications or supplements within 7 days prior to D1 (except for contraception, paracetamol and standard dose of multivitamins).
• Participant has used more than 5 cigarettes per day, or equivalent with other nicotine containing products, in the 3 months prior to Day 1, or is unwilling to avoid nicotine use during confinement periods.
• Participant who consumes on average more than 14 units of alcohol per week for female or 21 units of alcohol per week for male in the 6 months prior to Day 1 (1 unit = 10 mg alcohol), or who has a positive alcohol breath test at Screening or Day -1.
• History of excessive or dependent alcohol or drug use or addiction issues in the two years prior to screening, or participants who are positive for drug testing at screening or Day-1.
• Receipt of a live vaccine within 2 months prior to the Baseline visit (participants must agree to avoid live vaccination until at least 3 months after last dose of study drug).
• Receipt of an inactivated vaccine such as COVID-19 vaccination or influenza vaccination, within 14 days prior or planning to receive inactivated vaccine within 14 days post study treatment administration.
• Pregnant or lactating women.
• Cannot commit to full participation in all trial procedures.
• Any other circumstances that, in the Investigator (or designee) judgment, may increase the risk associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.
• Known exposure to anti-TL1A or any type of anti-TL1A therapy.
• Known exposure to anti-IL23 or any type of anti-IL23 therapy.
• Participants who have donated blood and/or plasma or lost a significant amount of blood (> 400 mL) within 30 days prior to screening, or who plan to donate blood during the entire study period of 24 weeks (12 weeks for participants receiving placebo).
• Participants who have received any other investigational agent or participated in any medical device clinical studies within 30 days or 5 half-lives, whichever is longer prior to screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Double

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SAD Cohort 1; 8 participants will receive in a 3:1 ratio of a single dose of SAD Dose Level 1 of TL-003 or placebo.	Drug: Placebo; Intravenously administered; Drug: TL-003; Intravenously administered
Experimental: SAD Cohort 2; 8 participants will receive in a 3:1 ratio of a single dose of SAD Dose Level 2 of TL-003 or placebo.	Drug: Placebo; Intravenously administered; Drug: TL-003; Intravenously administered
Experimental: SAD Cohort 3; 8 participants will receive in a 3:1 ratio of a single dose of SAD Dose Level 3 of TL-003 or placebo.	Drug: Placebo; Intravenously administered; Drug: TL-003; Intravenously administered
Experimental: SAD Cohort 4; 8 participants will receive in a 3:1 ratio of a single dose of SAD Dose Level 4 of TL-003 or placebo.	Drug: Placebo; Intravenously administered; Drug: TL-003; Intravenously administered
Experimental: MAD Cohort 1; 8 participants will receive in a 3:1 ratio of a single dose of MAD Dose Level 1 of TL-003 or placebo.	Drug: Placebo; Intravenously administered; Drug: TL-003; Intravenously administered
Experimental: MAD Cohort 2; 8 participants will receive in a 3:1 ratio of a single dose of MAD Dose Level 2 of TL-003 or placebo.	Drug: Placebo; Intravenously administered; Drug: TL-003; Intravenously administered

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and severity of Treatment Emergent Adverse Events adverse events (TEAEs)	Incidence and severity of AEs, including clinical relevant findings from the clinical laboratory tests (hematology, urinalysis, blood chemistry), physical examination, vital signs, 12-lead ECGs.	Up to 169 Days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to maximum concentration (Tmax)	Time at which Cmax is observed after infusion (tmax)	Up to 169 Days
Maximum concentration (Cmax)	Maximum observed concentration (Cmax) after infusion	Up to 169 Days
Area under the concentration-time curve from time 0 to last measurable time-point (AUC0-t)	The area under the plasma concentration-time curve from time 0 to the last measurable time-point (AUC0-t).	Up to 169 Days
Area under the concentration-time curve from time 0 to infinity (AUC0-inf)	The area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-inf).	Up to 169 Days
Terminal half-life (t1/2)	The time required for the plasma concentration of the drug to decrease by 50% during the terminal elimination phase	Up to 169 Days
Apparent clearance (CL)	The volume of plasma cleared of drug per unit time.	Up to 169 Days
Apparent volume of distribution (Vz)	The theoretical volume into which a drug distributes in the body.	Up to 169 Days
Terminal elimination rate constant (λz)	The rate of drug elimination during the terminal phase of the concentration-time curve.	Up to 169 Days
Percentage of AUC0-inf obtained by extrapolation (%AUCex)	Percentage of the area under the concentration-time curve from time zero to infinity obtained by extrapolation (%AUCex)	Up to 169 Days
Accumulation ratio (Rac)	The extent of drug accumulation at steady state compared to the first dose.	Up to 169 Days

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in the serum concentration of pre-specified pharmacodynamic biomarker over time	Change from baseline in the serum concentration of pre-specified pharmacodynamic biomarker over time.	Up to 169 Days
Incidence of anti-drug antibody (ADA)	The percentage of participants developing ADA.	Up to 169 Days
Titer of anti-drug antibody (ADA)	Titer will be measured using an ELISA and reported as endpoint dilution.	Up to 169 Days

Collaborators and Investigators

• Sponsor: TrueLab Biopharmaceutical Co., Ltd
• Collaborators: SAPRO Consulting Pty Ltd

Study record dates

Study Major Dates

• Study Start (Actual): April 8, 2026
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): April 1, 2027

Study Registration Dates

• First Submitted: April 6, 2026
• First Submitted That Met QC Criteria: April 6, 2026
• First Posted (Actual): April 13, 2026

Study Record Updates

• Last Update Posted (Actual): May 15, 2026
• Last Update Submitted That Met QC Criteria: May 12, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: TL-003-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: TrueLab will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No